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The identification of unique cell-surface proteins expressed
on tumor cells, yet not expressed on normal tissues, has
been challenging for pediatric malignancies. The cell sur-
face tyrosine kinase ALK (CD246, anaplastic lymphoma
kinase) is a promising target for neuroblastoma in that it is
expressed in either native, mutated, or over-expressed
forms on the plasma membrane surface. We identified
antibodies that bind to ALK, sequenced their variable
regions, and used this sequence information to construct
chimeric antigen receptors (CARs). Primary human T lym-
phocytes were then transduced with retroviral gene vectors
expressing a series of ALK-specific CARs, that included
different structural and signaling motifs. Transduced
T cells demonstrated ALK-specific cytolytic activity against
ALK-expressing tumors and produced Th1 cytokines upon
culture in the presence of tumor. In exploring different
iterations of CAR protein domain structure we found that
the scFv domains created from the heavy and light variable
domains of ALK-specific immunoglobulin could be inter-
changed with respect to their orientation in the context of
CAR tertiary protein structure. Moreover, ALK-specific
scFv functioned whether expressed in a short format, that
is as a single domain proximal to the T cell membrane, or
in a long format, that is extended away from the plasma
membrane using an IgG1-derived spacer domain com-
posed of CH2 and CH3. Using a xenogeneic NSG mouse
model for neuroblastoma, human ALK-specific CAR-
expressing T cells were found eradicate ALK-positive
tumor, when IL-7 was included to support T cell persis-
tence. These data argue for the continued evaluation of
ALK-specific CARs in pre-clinical studies.
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